MedElevator
Войти в исследования Circulation journal : official journal of the Japanese Circulation Society · 2020
Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deguchi Hiroko, Ikeda Masataka, Ide Tomomi, Tadokoro Tomonori, Ikeda Soichiro, Okabe Kosuke, Ishikita Akihito, Saku Keita, Matsushima Shouji, Tsutsui Hiroyuki
Аннотация
BACKGROUND: Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury.
METHODS AND RESULTS: RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.
CONCLUSIONS: RXD pretreatment may be a novel strategy against I/R injury.
METHODS AND RESULTS: RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.
CONCLUSIONS: RXD pretreatment may be a novel strategy against I/R injury.